Abstract
Sunitinib is an oral multiple tyrosine kinase receptor inhibitor. It is usually well tolerated but can cause fatigue, malaise, and rash. Sunitinib-induced cardiotoxicity has been well described, but nephrotoxicity is very rare. Here, we report a rare case of acute renal failure caused by sunitinib therapy in a 73-year-old Caucasian female who was enrolled in a phase II trial of sunitinib therapy for clear cell ovarian cancer. At presentation, her blood urea nitrogen (BUN) was 91 mg/dl and creatinine was 9.2 mg/dl. Sunitinib therapy was discontinued, and she was treated conservatively with intravenous fluid. Creatinine gradually returned to normal, and fatigue resolved. She was diagnosed with sunitinib-induced acute renal failure. The nephrologists and oncologists should be aware of sunitinib-induced rare nephrotoxicity, and patients should be closely monitored.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.
Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009;122(4):322–8.
Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2008;19(9):1613–8.
Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9.
Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin pract. 2011;117(4):c312–9.
Chen SY, Kao PC, Lin ZZ, Chiang WC, Fang CC. Sunitinib-induced myxedema coma. Am J Emerg Med. 2009;27(3):370e1–e3.
Lim TJ, Lee JH, Chang SG, Lee CH, Min GE, Yoo KH, et al. Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate. Urol Int. 2010;85(4):475–8.
Rodriguez-Reimundes E, Perazzo F, Vilches AR. Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib. Medicina. 2011;71(2):158–60.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kawsar, H.I., Bansal, S. & Myles, J.L. Acute renal failure: a rare side effect of sunitinib therapy. Med Oncol 29, 3594–3596 (2012). https://doi.org/10.1007/s12032-012-0272-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-012-0272-2